After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering

Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology.

The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses more on health-related applications for the technology, such as its immuno-oncology work with CAR-T therapy, Calyxt, an agriculture-focused gene-editing company based in the US, is using it to develop healthier and more nutritious food such as soybeans and wheat.

Attracted by this great tech offering, Bayer licensed a number of patents for Calyxt’s TALEN products in December 2013. Believing these had been breached, Calyxt filed a complaint in March this year. Settlement of these claims was filed earlier this week in Delaware. While financial terms were not disclosed, Bayer committed to destroy all technology, products and information relating to the disputed patents and will abandon any relevant new patent applications. Bayer and its subsidiaries will have no further access to Calyxt technology or intellectual property in the future.

The public offering will give the company the opportunity to raise €40.7M ($48.1M) to help move forward its high-oleic soybean and high-fibre wheat programmes, as well as to develop new products. Calyxt also plans to grant underwriters the opportunity to purchase additional shares worth approximately €6.1M ($7.2M).


Images by  Sima, Shutterstock.

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.